Method for the treatment of amyloidoses

• US 8,895,004 B2
• Filed: 02/27/2008
• Issued: 11/25/2014
• Est. Priority Date: 02/27/2007
• Status: Active Grant

• Current Assignee: Abbvie Deutschland GmbH & Company KG (Abbvie Incorporated)
• Original Assignee: Abbvie Deutschland GmbH & Company KG (Abbvie Incorporated)
• Inventors: Nimmrich, Volker, Barghorn, Stefan, Ebert, Ulrich, Hillen, Heinz, Gross, Gerhard, Draguhn, Andreas, Bruhl, Claus, Grimm, Christine, Krantz, Carsten
• Primary Examiner(s): BALLARD, KIMBERLY
• Application Number:
  US12/529,467
• Publication Number:
  US 20110130549A1
• Time in Patent Office: 2,463 Days
• US Class Current: 424/139.1
• CPC Class Codes: A61K 31/015 carbocyclic
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00

Abstract

The present invention relates to a method for the treatment of an amyloidosis such as Alzheimer'"'"'s disease in a subject in need thereof, characterized in that it comprises administering an inhibitor of the interaction between Aβ globulomer and the P/Q type voltage-gated presynaptic calcium channel to said subject.

Claims

1. A method for the treatment of an amyloidosis disease comprising administering to a subject in need thereof an agent that inhibits the interaction between Aβ

globulomer and P/Q type voltage-gated presynaptic calcium channel, wherein the agent is an antibody that binds to the P/Q type voltage-gated presynaptic calcium channel, wherein the amyloidosis disease is selected from the group consisting of Alzheimer'"'"'s disease and Down'"'"'s syndrome, wherein the antibody is raised against a peptide mapping near the C-terminus of the α

1A subunit of the P/Q type voltage-gated presynaptic calcium channel, and wherein the antibody is sc-16228.

2. The method of claim 1, wherein the treatment is for the restoration of memory function.

3. The method of claim 1, wherein the treatment is for the restoration of performance of activities of daily living (ADL) capacity.